维多利亚老品牌76696vic-在线入口

Be the most trusted biotech company

2022-01-27

First Patient Dosed in the Phase 2 Clinical Trial in LCH/ECD of Henlius BRAF Inhibitor HLX208
2022-01-20

The preclinical and structural analysis results of Henlius’ innovative anti-PD-1 mAb serplulimab, published in an international journal PLOS ONE
2022-01-18

Accelerating the Innovation Pipeline, Henlius BRAF Inhibitor HLX208 IND for Phase 1b/2 Studies Approved by NMPA
2022-01-04

Henlius Novel Anti-4-1BB×EGFR Bispecific Antibody HLX35 IND approved by NMPA
2021-12-28

Phase 3 clinical results of adalimumab biosimilar 汉达远® in psoriasis patients, published in an international journal Advances in Therapy
2021-12-21

The Phase 2 IND application of innovative PD-1 inhibitor serplulimab in combination with innovative anti-EGFR mAb HLX07 for the treatment of solid tumours was granted by the NMPA
2021-12-17

Henlius' anti-PD-1 mAb MRCT achieved 15.38 months OS in first-line treatment of SCLC, reducing the risk of death by 38% of the overall population
2021-12-09

Pre-clinical and preliminary Phase 1 clinical results of Henlius HLX07, a novel anti-EGFR mAb, published in well-known journal EXPERT OPIN BIOL TH
2021-12-07

Henlius’ Phase 3 clinical study of novel PD-1 inhibitor serplulimab for the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC) meets primary study endpoint